Médecins Sans Frontières & Merck Group

Médecins Sans Frontières: Frontline medical charity warning of alarming spread, facing operational challenges and attacks. Its capacity is stretched, affecting its ability to respond.

Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.

Médecins Sans Frontières: Médecins Sans Frontières is providing frontline care and warning of insufficient support, underscoring the humanitarian crisis. Its operations are vital but strained.

Merck Group: Merck Group is the developer of Ervebo, the only approved Ebola vaccine, which is being deployed in the DRC outbreak. Its role is central, and successful cross-protection could expand its market and reputation.

Médecins Sans Frontières: Providing frontline medical care and warning the outbreak is spreading at an 'alarming and unprecedented rate'. Its operations are vital in affected areas.

Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.

Médecins Sans Frontières: MSF urged Gilead to expand access to lenacapavir, highlighting affordability concerns.

Merck Group: Announced plans to allow generic production of alimatravir, potentially expanding market access.